Literature DB >> 30666781

Outcomes and prognostic variables associated with primary abdominal visceral soft tissue sarcomas in dogs: A Veterinary Society of Surgical Oncology retrospective study.

Dan Linden1, Julius M Liptak2, Arathi Vinayak3, Janet A Grimes4, Maninder Sandey1, Whitney Smiley5, Brad M Matz1.   

Abstract

Primary abdominal visceral soft tissue sarcomas (STSs) are rare tumours in dogs with little information available on outcomes. The goal of this retrospective, multi-institutional study was to describe the common tumour types, location and prognostic factors associated with primary abdominal visceral STSs. Medical records were searched for dogs with primary abdominal visceral STSs at six institutions and were retrospectively reviewed. Tumours were graded using the previously described grading scheme for STSs of the skin and subcutis when information in the histopathology report contained adequate details. Forty-two dogs were included in the study. Five dogs had grade I tumours, 11 had grade II and 15 had grade III tumours. The most common tumour type was leiomyosarcoma (38.1%). The most common tumour locations were the spleen (47.6%) and small intestine (23.8%). The local recurrence rate was low (4.7%). Metastasis was present at the time of surgery in 23.8%, and the overall metastatic rate was 40.4%. Mitotic index of ≥9 was associated with significantly shorter survival time (MST 269 days) compared with a mitotic index of <9 (MST not reached). The MST for grade I STSs was not reached, was 589 days for grade II and 158 days for grade III. Dogs with grade III tumours were more likely to develop metastatic disease. Neither location of the primary tumour nor the histologic subtype was associated with survival time. Histologic grading of abdominal visceral STSs using the previously described scheme is prognostic and should be provided on histopathology reports.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  dogs; oncology; sarcoma; soft tissue sarcoma; visceral

Year:  2019        PMID: 30666781     DOI: 10.1111/vco.12456

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  4 in total

1.  Canine Non-Angiogenic, Non-Myogenic Splenic Stromal Sarcoma: a Retrospective Clinicopathological Analysis and Investigation of Podoplanin as a Marker of Tumour Histogenesis.

Authors:  Brittany M Wittenberns; Douglas H Thamm; Eric P Palmer; Daniel P Regan
Journal:  J Comp Pathol       Date:  2021-08-27       Impact factor: 1.083

2.  Epidemiology and Survival of Dogs Diagnosed with Splenic Lymphoid Hyperplasia, Complex Hyperplasia, Stromal Sarcoma and Histiocytic Sarcoma.

Authors:  Cleide H Spröhnle-Barrera; Jayne McGhie; Rachel E Allavena; Helen C Owen; Chiara Palmieri; Tamsin S Barnes
Journal:  Animals (Basel)       Date:  2022-04-08       Impact factor: 3.231

3.  Clinicopathologic features and biologic behavior of canine splenic nodules with stromal, histiocytic and lymphoid components.

Authors:  Silvia Sabattini; Antonella Rigillo; Greta Foiani; Laura Marconato; Marta Vascellari; Alessandra Greco; Chiara Agnoli; Maurizio Annoni; Erica Melchiotti; Michela Campigli; Silvia Lucia Benali; Giuliano Bettini
Journal:  Front Vet Sci       Date:  2022-08-12

4.  Primary Ureteral Hemangiosarcoma in a dog.

Authors:  Joseph A Polit; Elisabeth V Moore; Ember Epperson
Journal:  BMC Vet Res       Date:  2020-10-12       Impact factor: 2.741

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.